Astellas Reports Q1 FY2025 U.S. Sales of IZERVAY at $110M

Astellas Pharma reported US sales of IZERVAYTM (avacincaptad pegol) for treating geographic atrophy secondary to age-related macular degeneration at ¥15.9 billion ($110 million) in Q1 FY2025. The preliminary figures were disclosed during an investment community meeting, with full financial results to be announced on July 30, 2025.

Astellas Pharma has reported US sales of IZERVAYTM (avacincaptad pegol) for treating geographic atrophy secondary to age-related macular degeneration (AMD) at ¥15.9 billion ($110 million) in Q1 FY2025, according to preliminary figures disclosed during an investment community meeting. The full financial results are expected to be announced on July 30, 2025.

Meanwhile, Alcon, a subsidiary of Johnson & Johnson, has announced its intention to acquire LumiThera, Inc., a leader in light-based innovations for ophthalmology. The acquisition includes LumiThera's photobiomodulation (PBM) device, which has demonstrated meaningful visual improvement in early and intermediate dry AMD patients. The PBM device is the only technology that has shown such results over two years of treatment [2].

Astellas Pharma is also conducting a Phase 3/4 clinical study to assess the safety of intravitreal administration of ASP3021 in participants in Japan with geographic atrophy secondary to AMD. The study aims to evaluate the safety and tolerance of ASP3021 eye injections in Japanese individuals aged 40 and older suffering from geographic atrophy due to AMD. This research is significant as AMD is a leading cause of vision loss, and geographic atrophy represents an advanced stage of the disease [1].

The ongoing study by Astellas Pharma could influence its stock performance positively, as successful results may enhance investor confidence and market position in the ophthalmology sector. This is particularly relevant given the competitive landscape of AMD treatments, where advancements can significantly impact market dynamics.

The acquisition by Alcon of LumiThera's PBM device, which has demonstrated meaningful visual improvement in early and intermediate dry AMD patients, could also have market implications. The device uses low-level light to stimulate mitochondrial energy production, promoting retinal cellular health. It is administered while the patient is sitting comfortably in a clinic setting and has shown visual acuity improvement with no treatment-related serious adverse events reported [2].

Both developments underscore the growing focus on innovative treatments for AMD, a leading cause of blindness in developed nations. The ongoing studies and acquisitions reflect the industry's commitment to advancing treatments for this progressive and debilitating condition.

References:
[1] https://www.tipranks.com/news/company-announcements/astellas-pharmas-new-study-on-asp3021-a-potential-game-changer-for-amd-treatment-2?mod=mw_quote_news
[2] https://www.businesswire.com/news/home/20250702399355/en/Alcon-to-Acquire-LumiThera-and-Its-Photobiomodulation-Device-for-the-Treatment-of-Early-and-Intermediate-Dry-Age-Related-Macular-Degeneration-AMD